InvestorsHub Logo
Followers 8
Posts 1427
Boards Moderated 0
Alias Born 06/30/2016

Re: tilator post# 31270

Monday, 11/13/2017 4:19:53 PM

Monday, November 13, 2017 4:19:53 PM

Post# of 38634
Tilator, honestly, you are not this naive are you? selling the generic is just like selling any other drug. it costs millions. you need to package it. You need to distribute it. your talking about putting it on a pharmacy shelf LOL. in my area alone there are over 100 pharmacies. do you know how many tricks and people that would take just to stop at each one? thats why pharmacies deal with distributors who lock in deals where they MUST buy from them. hence why new arrivals like MNK and seroquel are squeezed out of the market for the first year or so. you cant just walk up to a pharmacy and peddle a drug like a back alley narcotic sale. LOL

you keep saying, your not looking back but what the company has now. you are correct they have 2 approvals. but they just need to partner them. if the company partnered each generic they have and each generic brings in just 4 million a year. only 1 million a quarter. the company would generate 36 million a year. Thats just on the generics. they do not need to get involved in any sales or distribution. just get them approved and get them partnered. 1 million a quarter per drug. they spend 13 million a year in operating csts which gives them 23 million a year profit. they could then continue the research and partner the NDA's get another 15 million in up front costs. and now your talking 38 million in profit. thats a dollar a share! do that for his pie in the sky 20 opiods and for the next 20 years the company is making $1 a share PROFIT. based on next to nothing revenue and partnerships. then we are not even talking about revenue from those NDAs !

The original business model would have worked. he got greedy and wasnt happy to only get $15 million up front and look where we are. NOTHING is moving.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPCI News